Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells - Related Studies

Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells (CLIPA)

This study is currently recruiting participants.

Study NCT00078520. Last updated on May 7, 2008. Information provided by Baylor College of Medicine

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Leukemia
		Leukemia, B-Cell, Chronic

2	Additional conditions recognized in this trial
		Leukemia, B-Cell
		Leukemia, Lymphocytic, Chronic, B-Cell

3	More general conditions related to this trial
		Immune System Diseases
		Immunoproliferative Disorders
		Leukemia, Lymphoid
		Lymphatic Diseases
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type

4	Additional drug interventions recognized in this trial
		Interleukin-2

5	More general drug interventions related to this trial
		Analgesics
		Analgesics, Non-Narcotic
		Antineoplastic Agents
		Central Nervous System Agents
		Peripheral Nervous System Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Sensory System Agents
		Therapeutic Uses

6	Sponsors listed in this trial
		Baylor College of Medicine
		The Methodist Hospital System
		Center for Cell and Gene Therapy